These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 13952193)

  • 41. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 42. [Methyl-dopa (Aldomet), a new principle in the treatment of high blood pressure].
    MATHISEN HS
    Tidsskr Nor Laegeforen; 1962 Mar; 82():353-5. PubMed ID: 14471146
    [No Abstract]   [Full Text] [Related]  

  • 43. [Pepsin-forming ability of gastric mucosa under effect of DOPA and alpha-methyl-DOPA].
    Grechishkin LL
    Farmakol Toksikol; 1969; 32(5):556-8. PubMed ID: 4903696
    [No Abstract]   [Full Text] [Related]  

  • 44. Methyldopa in hypertension.
    DOLLERY CT
    Am Heart J; 1963 Jan; 65():139-40. PubMed ID: 14028479
    [No Abstract]   [Full Text] [Related]  

  • 45. Metabolic studies in carcinoid syndrome: observations on use of alpha-methyl DOPA, isonicotinic acid hydrazide and selective tryptophan deficiency.
    DAVIS RB; ALEXANDER CS; ADICOFF A
    Metabolism; 1961 Dec; 10():1035-44. PubMed ID: 13883956
    [No Abstract]   [Full Text] [Related]  

  • 46. [Drug allergy damage to the blood ].
    Müller U
    Schweiz Med Wochenschr; 1975 Aug; 105(34):1065-72. PubMed ID: 1166294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [5-HYDROXYTRYPTOPHAN DOPA DECARBOXYLASE IN NERVOUS AND CARDIAC TISSUES IN THE MOLLUSC HELIX POMATIA. INTERACTION OF SUBSTRATES IN VITRO].
    CARDOT J
    C R Hebd Seances Acad Sci; 1964 Jul; 259():902-4. PubMed ID: 14190531
    [No Abstract]   [Full Text] [Related]  

  • 48. [THE PSYCHOPHYSIOLOGICAL EFFECTS OF METHYLDOPA].
    SAINTJEAN A; DONALD MW; BAN TA
    Union Med Can; 1963 Dec; 92():1420-2. PubMed ID: 14101831
    [No Abstract]   [Full Text] [Related]  

  • 49. A drug-specific leuco-agglutinin in a fatal case of agranulocytosis due to chlorpromazine.
    HOFFMAN GC; HEWLETT JS; GARZON FL
    J Clin Pathol; 1963 May; 16(3):232-4. PubMed ID: 13963921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effect of administration of amino acids, especially of L-DOPA and -methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. 3. Alterations of cerebrospinal fluid in patients with Huntington's chorea after -methyldopa or L-DOPA].
    Simanyi M; Gerstenbrand F; Gründig E; Schedl R; Weiss H
    Z Neurol; 1973 Mar; 204(1):67-80. PubMed ID: 4121504
    [No Abstract]   [Full Text] [Related]  

  • 51. [Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].
    Lhermitte F; Agid Y; Feuerstein C; Serre F; Signoret JL; Studler JM; Bonnet AM
    Rev Neurol (Paris); 1977; 133(8-9):445-54. PubMed ID: 929037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Drug allergy in agranulocytosis, hemorrhagic aleukia, and panmyelophthisis].
    KOST EA
    Klin Med (Mosk); 1952 Dec; 30(12):31-6. PubMed ID: 13035987
    [No Abstract]   [Full Text] [Related]  

  • 53. [Facilitation of the effects of L-DOPA by alpha-methyldopa].
    Uspenskiĭ AE; Korobov NV
    Biull Eksp Biol Med; 1976 Mar; 81(3):314-6. PubMed ID: 986203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Allergic blood diseases].
    FLEISCHHACKER H
    Wien Klin Wochenschr; 1963 Feb; 75():77-80. PubMed ID: 13945468
    [No Abstract]   [Full Text] [Related]  

  • 55. Incorporation of L-dopa, L-alpha-methyldopa and DL-isoproterenol into guinea pig hair.
    Harrison WH; Gray RM; Solomon LM
    Acta Derm Venereol; 1974; 54(4):249-53. PubMed ID: 4136810
    [No Abstract]   [Full Text] [Related]  

  • 56. L-dopa or methyldopa?
    Tice LF
    Am J Pharm Sci Support Public Health; 1972; 144(3):71-2. PubMed ID: 5068775
    [No Abstract]   [Full Text] [Related]  

  • 57. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 58. [Schultz Agranulocytosis. A drug-allergy blood disease].
    Hartl W
    Med Welt; 1971 Jun; 23():967-9. PubMed ID: 5579285
    [No Abstract]   [Full Text] [Related]  

  • 59. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 60. NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1989 Mar; 348():1-184. PubMed ID: 12704436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.